Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Novartis
Company Monitoring Page for Novartis
latest headlines for company on cafepharma
Novartis expats detail their health-tech spinoff DatosX
Medical Marketing and Media
Wed, 10/11/23 - 11:44 pm
Tags:
Novartis
,
innovation
,
digital health
,
spinoffs
,
DatosX
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Fierce Biotech
Tue, 10/10/23 - 11:36 am
Tags:
Novartis
,
Cadent Therapeutics
,
major depressive disorder
,
MIJ821
Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A
Fierce Biotech
Mon, 10/9/23 - 11:12 am
Tags:
AstronauTx
,
Novartis
,
Alzheimer's disease
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation
BioSpace
Mon, 10/9/23 - 10:14 am
Tags:
Novartis
,
Cosentyx
,
FDA
,
ankylosing spondylitis
,
psoriatic arthritis
,
non-radiographic axial spondyloarthritis
Novartis' Sandoz dips on debut after lower than expected valuation
Reuters
Wed, 10/4/23 - 09:43 am
Tags:
Novartis
,
Sandoz
,
spinoffs
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Clinical Trials Arena
Mon, 10/2/23 - 10:14 am
Tags:
Novartis
,
clinical trials
,
iptacopan
,
IgA nephropathy
,
kidney disease
Adlai Nortye IPO gives old Novartis cancer drug new life
BioPharma Dive
Fri, 09/29/23 - 10:22 am
Tags:
Adlai Nortye
,
IPOs
,
Novartis
,
AN2025
,
head and neck cancer
,
solid tumors
Novartis confirms Sandoz spin-off for October 4, 2023
Reuters
Mon, 09/25/23 - 07:45 pm
Tags:
Novartis
,
Sandoz
,
spinoffs
Novartis eyes first-line use of Lutathera after trial win
Pharmaphorum
Mon, 09/25/23 - 11:41 am
Tags:
Novartis
,
radioligands
,
clinical trials
,
neuroendocrine tumors
,
Lutathera
FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies
BioSpace
Sun, 09/24/23 - 08:52 pm
Tags:
FDA
,
ARS Pharmaceuticals
,
Novartis
,
Taysha
,
Alvotech
,
Intarcia
Novartis hit with another serious drug marketing breach, this time for multiple sclerosis therapy Mayzent
Fierce Pharma
Thu, 09/21/23 - 10:36 am
Tags:
Novartis
,
UK
,
PMCPA
,
pharma marketing
,
Mayzent
BeiGene to go solo with cancer drug after Novartis deal termination
Yahoo/Reuters
Tue, 09/19/23 - 10:30 am
Tags:
BeiGene
,
Novartis
,
cancer
,
tislelizumab
,
Tivimbra
Bausch + Lomb seeks funding for eye drug acquisition from Novartis
BioPharma Dive
Wed, 09/13/23 - 11:32 am
Tags:
Bausch + Lomb
,
Novartis
,
M&A
,
Xiidra
Novartis recalls Sandimmune oral solution due to crystal formation
Pharmaceutical Technology
Tue, 09/12/23 - 07:14 pm
Tags:
Novartis
,
product recalls
,
Sandimmune
,
organ transplants
Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
BioSpace
Mon, 09/11/23 - 12:02 pm
Tags:
Novartis
,
GT005
,
gene therapy
,
geographic atrophy
,
Gyroscope Therapeutics
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Fierce Pharma
Fri, 09/8/23 - 10:29 am
Tags:
M&A
,
patent cliffs
,
Merck
,
JNJ
,
Pfizer
,
GSK
,
Novartis
,
Eli Lilly
,
Novo Nordisk
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
Tags:
R&D
,
biotech
,
Merck
,
sotatercept
,
Daiichi Sankyo
,
AstraZeneca
,
Dato-DXd
,
Novo Nordisk
,
CagriSema
,
Eli Lilly
,
donanemab
,
Karuna Therapeutics
,
Zai Lab
,
KarXT
,
Moderna Therapeutics
,
mRNA-1647
,
Novartis
,
iptacopan
,
Madrigal Pharmaceuticals
,
resmetirom
,
Cytokinetics
,
aficamten
,
Roche
,
Chugai
,
tiragolumab
Novartis names new board member after international boss steps down
Reuters
Wed, 09/6/23 - 10:06 am
Tags:
Novartis
,
executives
,
Patrick Horber
,
Marie-France Tschudin
Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list
Fierce Pharma
Tue, 09/5/23 - 08:54 pm
Tags:
Novartis
,
legal
,
Inflation Reduction Act
,
CMS
,
drug pricing
,
Entresto
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Motley Fool
Tue, 09/5/23 - 08:39 pm
Tags:
Novartis
,
biosimilars
,
Eylea
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.